F Hong1, T M Habermann2, L I Gordon3, H Hochster4, R D Gascoyne5, V A Morrison6, R I Fisher7, N L Bartlett8, P J Stiff9, B D Cheson10, M Crump11, S J Horning12, B S Kahl13. 1. Dana Farber Cancer Institute, Boston, MA. Electronic address: fxhong@jimmy.harvard.edu. 2. Mayo Clinic, Rochester, MN. 3. Northwestern University, Chicago, IL. 4. Yale University, New Haven, CT, USA. 5. British Columbia Cancer Agency, Vancouver, Canada. 6. University of Minnesota, VA Medical Center, Minneapolis, MN. 7. Fox Chase Cancer Center, Philadelphia, PA. 8. Washington University, St Louis, MO. 9. Loyola University, Maywood, IL. 10. Georgetown University Hospital, Washington, DC, USA. 11. Princess Margaret Hospital, Toronto, Ontario, Canada. 12. Genentech, Inc., South San Francisco, CA. 13. University of Wisconsin, Madison, WI, USA.
Abstract
BACKGROUND: The role of body mass index (BMI) in survival outcomes is controversial among lymphoma patients. We evaluated the association between BMI at study entry and failure-free survival (FFS) and overall survival (OS) in three phase III clinical trials, among patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin's lymphoma (HL). PATIENTS AND METHODS: A total of 537, 730 and 282 patients with DLBCL, HL and FL were included in the analysis. Baseline patient and clinical characteristics, treatment received and clinical outcomes were compared across BMI categories. RESULTS: Among patients with DLBCL, HL and FL, the median age was 70, 33 and 56; 29%, 29% and 37% were obese and 38%, 27% and 37% were overweight, respectively. Age was significantly different among BMI groups in all three studies. Higher BMI groups tended to have more favorable prognosis factors at study entry among DLBCL and HL patients. BMI was not associated with clinical outcome with P-values of 0.89, 0.30 and 0.40 for FFS, and 0.64, 0.67 and 0.09 for OS, for patients with DLBCL, HL and FL, respectively. The association remains non-significant after adjusting for other clinical factors in the Cox model. A subset analysis of males with DLBCL treated on R-CHOP revealed no differences in FFS (P = 0.48) or OS (P = 0.58). CONCLUSION:BMI was not significantly associated with clinical outcomes among patients with DLBCL, HD or FL, in three prospective phase III clinical trials. The findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.
RCT Entities:
BACKGROUND: The role of body mass index (BMI) in survival outcomes is controversial among lymphomapatients. We evaluated the association between BMI at study entry and failure-free survival (FFS) and overall survival (OS) in three phase III clinical trials, among patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin's lymphoma (HL). PATIENTS AND METHODS: A total of 537, 730 and 282 patients with DLBCL, HL and FL were included in the analysis. Baseline patient and clinical characteristics, treatment received and clinical outcomes were compared across BMI categories. RESULTS: Among patients with DLBCL, HL and FL, the median age was 70, 33 and 56; 29%, 29% and 37% were obese and 38%, 27% and 37% were overweight, respectively. Age was significantly different among BMI groups in all three studies. Higher BMI groups tended to have more favorable prognosis factors at study entry among DLBCL and HL patients. BMI was not associated with clinical outcome with P-values of 0.89, 0.30 and 0.40 for FFS, and 0.64, 0.67 and 0.09 for OS, for patients with DLBCL, HL and FL, respectively. The association remains non-significant after adjusting for other clinical factors in the Cox model. A subset analysis of males with DLBCL treated on R-CHOP revealed no differences in FFS (P = 0.48) or OS (P = 0.58). CONCLUSION: BMI was not significantly associated with clinical outcomes among patients with DLBCL, HD or FL, in three prospective phase III clinical trials. The findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.
Entities:
Keywords:
Hodgkin's lymphoma; body mass index; diffuse large B-cell lymphoma; follicular lymphoma; survival outcomes
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Relin Yang; Michael C Cheung; Felipe E Pedroso; Margaret M Byrne; Leonidas G Koniaris; Teresa A Zimmers Journal: J Surg Res Date: 2011-05-23 Impact factor: 2.192
Authors: Sandra Waalkes; Axel S Merseburger; Mario W Kramer; Thomas R W Herrmann; Gerd Wegener; Julia Rustemeier; Rainer Hofmann; Mark Schrader; Markus A Kuczyk; Andres J Schrader Journal: Cancer Causes Control Date: 2010-07-22 Impact factor: 2.506
Authors: C Tarella; D Caracciolo; P Gavarotti; C Argentino; F Zallio; P Corradini; D Novero; C Magnani; A Pileri Journal: Bone Marrow Transplant Date: 2000-12 Impact factor: 5.483
Authors: Leo I Gordon; Fangxin Hong; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Patrick J Stiff; Bruce D Cheson; Mary Gospodarowicz; Ranjana Advani; Brad S Kahl; Jonathan W Friedberg; Kristie A Blum; Thomas M Habermann; Joseph M Tuscano; Richard T Hoppe; Sandra J Horning Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Vicki A Morrison; Linda McCall; Hyman B Muss; Aminah Jatoi; Harvey J Cohen; Constance T Cirrincione; Jennifer A Ligibel; Jacqueline M Lafky; Arti Hurria Journal: J Geriatr Oncol Date: 2017-12-08 Impact factor: 3.599
Authors: Shama Jaswal; Vanessa Sanders; Priyanka Pullarkat; Stephanie Teja; Amber Salter; Marcus P Watkins; Norman Atagu; Daniel R Ludwig; Joyce Mhlanga; Vincent M Mellnick; Linda R Peterson; Nancy L Bartlett; Brad S Kahl; Todd A Fehniger; Armin Ghobadi; Amanda F Cashen; Neha Mehta-Shah; Joseph E Ippolito Journal: Cancers (Basel) Date: 2022-06-14 Impact factor: 6.575
Authors: Zheng Zhou; Alfred W Rademaker; Leo I Gordon; Ann S LaCasce; Allison Crosby-Thompson; Ann Vanderplas; Gregory A Abel; Maria A Rodriguez; Auayporn Nademanee; Mark S Kaminski; Myron S Czuczman; Michael M Millenson; Andrew D Zelenetz; Joyce Niland; Jonathan W Friedberg; Jane N Winter Journal: J Natl Compr Canc Netw Date: 2016-10 Impact factor: 11.908
Authors: Lukas Weiss; Thomas Melchardt; Alexander Egle; Georg Hopfinger; Hubert Hackl; Richard Greil; Juergen Barth; Mathias Rummel Journal: Ann Hematol Date: 2017-04-30 Impact factor: 3.673
Authors: Dai Chihara; Melissa C Larson; Dennis P Robinson; Carrie A Thompson; Matthew J Maurer; Carla Casulo; Priyanka Pophali; Brian K Link; Thomas M Habermann; Andrew L Feldman; Christopher R Flowers; James R Cerhan; Lindsay M Morton Journal: Leuk Lymphoma Date: 2021-06-14